Home › Biliary Tract Cancer › Virginia
Biliary Tract Cancer clinical trials in Virginia
9 studies for Biliary Tract Cancer are looking for participants at sites in Virginia.
Cities in Virginia
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- NEXT Oncology, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05482893A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295), Roanoke
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06428409Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Virginia Commonwealth University, VCU Health, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06282575Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Fairfax
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Fairfax
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 19, 2026 · NCT06467357A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.